Holen Sie sich die Stockscreener-App
33.47
3.37%
1.09
Handel nachbörslich:
33.46
-0.010
-0.03%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Form 144 ULTRAGENYX PHARMACEUTICAL INC. For: 1 July By Investing.com - Investing.com Canada
RARE (NASDAQ: RARE) affiliate reports insider sales and scheduled awards - Stock Titan
RAREUltragenyx Pharmaceutical Inc Latest SEC Filings - Finviz
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits
Does Ultragenyx (RARE) Shifting Into Small‑Cap Value Indices Recast Its Rare‑Disease Growth Story? - simplywall.st
Ultragenyx Pharmaceutical Inc.(NasdaqGS: RARE) added to Russell 2000 Index - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell Midcap Growth Benchmark - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) added to Russell 2000 Value Benchmark - marketscreener.com
Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock? - Yahoo Finance
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) added to Russell 2000 Growth Benchmark - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell 1000 Growth Benchmark - marketscreener.com
Price to book forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell 1000 Dynamic Index - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS: RARE) dropped from Russell 1000 Index - marketscreener.com
RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty - Stocktwits
Enterprise value to revenue forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Enterprise value to EBIT forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Price to sales forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Price to earnings forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Ultragenyx Pharmaceutical, Inc. Actuals & Estimates (NASDAQ:RARE) - TradingView
Ultragenyx Pharmaceutical, Inc. Actuals & Estimates (BX:UP0) - TradingView
RARE Forecast — Price Target — Prediction for 2027 - TradingView
Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity - Seeking Alpha
Ultragenyx Pharmaceutical Inc. $RARE Shares Bought by Caitong International Asset Management Co. Ltd - MarketBeat
Ultragenyx grants 44,409 restricted stock units to 15 new non-executive officers as an inducement. - Pluang
Ultragenyx awards 44,409 RSUs to 15 new hires - Stock Titan
Ultragenyx Pharmaceutical Inc (RARE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ultragenyx Pharmaceutical Inc - TradingKey
Ultragenyx Pharmaceutical Inc (RARE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ultragenyx Pharmaceutical Inc (RARE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ultragenyx Pharmaceutical Inc (RARE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ultragenyx Pharmaceutical Inc (RARE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ultragenyx Pharmaceutical Inc (RARE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ultragenyx Pharmaceutical Inc (RARE) Institutional Confidence - TradingKey
Why (RARE) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Ultragenyx (RARE) Is Up 17.6% After ESOP Share Shelf And Conference Spotlight On Gene Therapies – Has The Bull Case Changed? - simplywall.st
Insider Sell Alert: Sanders Corazon (Corsee) D. Sells Shares of Ultragenyx Pharmaceutical Inc (RARE) - GuruFocus
Ultragenyx EVP sells $46,753 in common stock By Investing.com - Investing.com Australia
Ultragenyx director Corazon D. Sanders sells $50,100 in stock - Investing.com
Ultragenyx EVP sells $46,753 in common stock - Investing.com
Ultragenyx director Corazon D. Sanders sells $50,100 in stock By Investing.com - Investing.com Canada
Ultragenyx (RARE) director sells 2,000 shares at $25.05 - Stock Titan
Ultragenyx (RARE) legal chief sells 1,899 company shares in open market - Stock Titan
[144] Ultragenyx Pharmaceutical Inc. SEC Filing - Stock Titan
RARE (NASDAQ) proposed sale of 2,000 restricted shares by broker-dealer - Stock Titan
Ultragenyx Pharmaceutical (RARE) Gains 1.5% as Stock Tests Key Resistance Near $25.57Stop Hunt - newsline.com
Here is Why Ultragenyx Pharmaceutical (RARE) is One of the Best Buy-the-Dip Stocks - Insider Monkey
Ultragenyx Pharmaceutical Inc. $RARE Stock Holdings Lifted by GW&K Investment Management LLC - MarketBeat
Motley Fool Wealth Management LLC Lowers Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Los Angeles Capital Management LLC Sells 60,515 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
RARE: Transformative year ahead with pivotal data, gene therapy launches, and path to profitability - TradingView
RARE: Phase III Angelman data and gene therapy launches set the stage for profitability by 2027 - TradingView
How The Ultragenyx Pharmaceutical (RARE) Investment Story Is Shifting With New Data And Street Views - Yahoo Finance
Ultragenyx Pharmaceutical Inc. $RARE Shares Acquired by BNP Paribas Financial Markets - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Institutional Confidence in GTX-102 Fuels Optimism for Ultragenyx Pharmaceutical (RARE) - Insider Monkey
3.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):